2023
PB0014 Do Antiphospholipid Antibodies Inform the Choice of Anticoagulant Agents in Patients with Atrial Fibrillation?
Bikdeli B, Bejjani A, Khairani C, Jimenez D, Monreal M, Siegal D, Kanthi Y, Barnes G, O’Donoghue M, Ruff C, Middeldorp S, Lopes R, Goldhaber S, Weitz J, Cushman M, Krumholz H, Lip G, Piazza G. PB0014 Do Antiphospholipid Antibodies Inform the Choice of Anticoagulant Agents in Patients with Atrial Fibrillation? Research And Practice In Thrombosis And Haemostasis 2023, 7: 100697. DOI: 10.1016/j.rpth.2023.100697.Peer-Reviewed Original Research
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviors